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Abstract
This analysis aims to describe the outcomes of two nonambulatory patients with Duchenne muscular dystrophy (DMD) who
participated in two clinical studies. The two consecutive trials of eteplirsen (studies 201 and 202) were conducted in patients with
DMD (N=12) and confirmed genetic mutations amenable to exon 51 skipping.
In study 201, 12 patients were randomized to receive once-weekly, double-blind intravenous infusions of eteplirsen 30 or 50mg/kg or
placebo for 24weeks;patients then receivedopen-label eteplirsenduringweeks25 through28.All 12patientscontinuedontoopen-label
extension study 202 and received long-term treatment with eteplirsen. We compared cardiac, pulmonary, and upper limb function and
dystrophin production in the nonambulatory twin patients versus the 10 ambulatory patients through 240 combined treatment weeks.
Ten study patients remained ambulatory through both studies, while the identical twin patients both experienced early, rapid loss of
ambulation. The twin patients had greater disease severity at baseline (6-minute walk test [6MWT], 330 and 256m) versus the other
patients (n=10; 6MWT range, 341–418m). They maintained cardiac and upper limb function through combined week 240, with
outcomessimilar to thoseof thepatientswho remainedambulatory.Dystrophinproductionwasconfirmed followingeteplirsen treatment.
Despite the loss of ambulation, other markers of disease progression remained relatively stable in the eteplirsen-treated twin
patients and were similar to those of the ambulatory patients.
Abbreviations: 6MWT = 6-minute walk test, BMI = body mass index, DMD = Duchenne muscular dystrophy, IV = intravenous,
LVEF = left ventricular ejection fraction, MVICT = maximum voluntary isometric contraction test, NC = normal control, PDPF =
percent dystrophin-positive fibers, PDVF = polyvinylidene difluoride, TEAE = treatment-emergent adverse event.
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Editor: Yan Li.
Source of funding: This study was sponsored by Sarepta Therapeutics, Inc.
Role of funding source: This study and manuscript were funded by Sarepta Therapeutics, Inc. Sarepta employees were involved in the study design, the collection,
analysis, and interpretation of data, the review of the manuscript, and the decision to submit for publication.
Conflicts of interest: Medical writing and editorial support were provided by Callie Grimes, PhD, and Barbara Zeman, PhD, of Peloton Advantage, LLC, an OPEN Health
company (Parsippany, NJ), and funded by Sarepta Therapeutics, Inc. L. N. Alfano, L. Cripe, R. Dracker, Z. Sahenk, and L. Lowes have no conflicts to disclose. J. S.
Charleston, J. Dworzak, H. Eliopoulos, D. E. Frank, K. Lucas, J. Lynch, E. Naughton, and F.J. Schnell are employees of Sarepta Therapeutics, Inc. and may own stock
or options in the company. C. Donoghue was an employee at the time of the study. A. M. Connolly has served on advisory boards for AveXis, Inc., Cytokinetics, Inc.,
Sanofi Genzyme, and Sarepta Therapeutics, Inc. She serves on the data management safety board for Catabasis Pharmaceuticals, Inc., and as an investigator for
AveXis, Inc., Biogen, Bristol-Myers Squibb, Cytokinetics, Inc., FibroGen, Italfarmeco SpA, NS Pharma, Inc., Pfizer Inc, PTC Therapeutics, Inc., and Sarepta
Therapeutics, Inc. S. Lewis is an employee of Nationwide Children’s Hospital, which received funding from Sarepta Therapeutics in the form of the study budget. A. J.
Milici serves as a remunerated consultant for Sarepta Therapeutics, Inc. A. Flynt is an employee of PharPoint Research, which received funding from Sarepta
Therapeutics for data analysis for the study. At the time of the study, L.R. Rodino-Klapac was an employee of Nationwide Children’s Hospital, which received funding
from Sarepta Therapeutics in the form of a research agreement; she is currently an employee of Sarepta Therapeutics, Inc., and may own stock/options in the
company. She is the inventor of technology that has been exclusively optioned to Sarepta Therapeutics. G. D. Young serves as a remunerated consultant for Sarepta
Therapeutics, Inc. J. R. Mendell serves on an advisory board for Sarepta Therapeutics, Inc.
a Pediatrics, Center for Gene Therapy, Nationwide Children’s Hospital, Columbus, OH, b Sarepta Therapeutics, Inc., Cambridge, MA, c Currently: Pediatrics, Center for
Gene Therapy, Nationwide Children’s Hospital, Columbus, OH, dDepartment of Neurology, Washington University School of Medicine, St. Louis, MO, e Summerwood
Pediatrics/Infusacare Medical Services, PC, Liverpool, NY, f Flagship Biosciences, Westminster, CO, g PharPoint Research, Durham, NC, hCurrently: Sarepta
Therapeutics, Inc., Cambridge, MA, USA.
∗
Correspondence: Lindsay N. Alfano, Research Physical Therapist, Neuromuscular Physical Therapy, Nationwide Children’s Hospital, Center for Gene Therapy, 700
Children’s Dr, Columbus, OH 43205, USA (e-mail: Lindsay.Alfano@nationwidechildrens.org).
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is
permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Medicine (2019) 98:26(e15858)






Duchenne muscular dystrophy (DMD) is a progressive, X-linked
recessive, degenerative, universally fatal neuromuscular disease
caused by lack of dystrophin that results in loss of ambulation
and wheelchair dependency by the early teens.[1,2] A primary
concern for nonambulatory patients and their caregivers is the
maintenance of respiratory and cardiac function, as respiratory
and cardiac deterioration are leading causes of death in patients
with DMD.[3–6] In addition, preservation of upper extremity
function[3] is important to maintain the ability to independently
engage in activities of daily living, including self-care (e.g., feeding
and grooming), computer use, writing, and control of manual or
powered wheelchairs. Most clinical trials of disease-modifying
agents for DMD focused on preservation of lower limb
function.[7,8] However, as DMD-associated morbidity is not
restricted to lower limb dysfunction, clinical assessments of
disease-modifying treatments should also focus on preservation
of pulmonary, cardiac, and upper limb function.
Eteplirsen (Exondys 51 [formerly AVI-4658]; Sarepta Thera-
peutics, Inc., Cambridge, MA) is the first DMD treatment
approved by the US Food and Drug Administration, and is
indicated for the treatment of DMD in patients with a genetically
confirmed DMD gene mutation that is amenable to exon 51
skipping.[9] Patients with certain deletion mutations adjacent to
exon 51 of the DMD gene produce an out-of-frame mRNA that
results in the production of an unstable or nonfunctional protein
product.[1] Eteplirsen targets exon 51 in dystrophin pre-mRNA
to trigger skipping of exon 51,[1] resulting in restoration of the
reading frame and allowing production of an internally truncated
but functional dystrophin protein.[9–11]
Data from two consecutive studies of 12 patients treated with
eteplirsen for up to 240 weeks at the time of this analysis were
previously compared with data for untreated controls[10] or with
natural history data.[12] These comparisons showed that long-
term treatment with eteplirsen slowed disease progression,
including measures of ambulatory and pulmonary function,
and had no negative impact on cardiac function.[10,12,13] Two
patients in the trial experienced early, rapid deterioration in
ambulation. In this observational study, we compare long-term
pulmonary, cardiac, and upper extremity function and dystro-
phin production in muscle biopsy samples obtained at week 180
in these two patients with that of 10 study patients who remained
ambulatory throughout the trial.
2. Materials and methods
2.1. Study design
Details of the design of eteplirsen studies 201 and 202 have been
described previously.[10] Briefly, study 201 (NCT01396239) was
a 28-week trial conducted from July 2011 to February 2012 that
comprised a 24-week double-blind phase and a 4-week open-
label phase. Patients were randomized 1:1:1 to receive once-
weekly, double-blind intravenous (IV) infusions of eteplirsen
(30 or 50mg/kg) or placebo for 24 weeks. Placebo patients were
then randomized 1:1 to receive eteplirsen 30 or 50mg/kg for
weeks 25 through 28. During the last visit of study 201, eligible
patients could be enrolled in study 202 (NCT01540409), an
open-label extension study designed to assess the long-term
efficacy and safety of eteplirsen, which initiated in February 2012
and ended in April 2016. A dose extension was completed and
ended in August 2017. Patients continued on the same dose of
eteplirsen through completion of study 202 (combined week 240
of studies 201 and 202). The studies were conducted in
accordance with the principles of the Declaration of Helsinki
and the International Council for Harmonisation Good Clinical
Practice guidelines, and the ethics committee at Nationwide
Children’s Hospital approved the study protocol. Parents or legal
guardians of all patients provided written informed consent
before study participation and genetic testing.
2.2. Patients
Eligible patients for study 201were aged 7 to 13 years with DMD
and a genetically confirmed mutation amenable to exon
51 skipping, were able to walk 200 to 400m (±10%) on the
6-minute walk test (6MWT), were receiving stable doses of oral
corticosteroids for at least 24 weeks before study entry, and
remained on stable corticosteroid therapy throughout the
study.[2] Patients who completed study 201 were eligible to
enroll in study 202, a long-term extension.
2.3. Functional efficacy
2.3.1. Ambulatory and pulmonary function assessments.
The 6MWT and pulmonary function tests were performed at
baseline, at least every 12 weeks through week 96, and every 24
weeks thereafter until week 240 andwere described previously.[10]
2.3.2. Cardiac function assessment. As part of safety
monitoring, standard 2-dimensional echocardiography (ECHO)
of left ventricular ejection fraction (LVEF) was performed at the
central site at baseline of study 201 and at prespecified time points
every 10, 12, 14, or 24 weeks thereafter, through combined study
week 240, to assess cardiac function.Medical personnel reviewed
each ECHO, noting LVEF and designating findings as clinically
or not clinically significant.
2.3.3. Upper limb functional assessments. The 9-Hole Peg
Test was administered at least every 24 weeks using methods
previously described.[14] The patient was timed on how quickly
he could take 9 pegs from a shallow bowl indentation in the
testing apparatus, place each peg into a hole one at a time, and
put the pegs back, one at a time, in the shallow bowl indentation.
Dominant and nondominant hands were tested twice, and the
shorter time was used for analysis. Results of the dominant hand
assessments are reported.
A maximum voluntary isometric contraction test (MVICT) was
performed every 12 weeks through week 96 and every 24 weeks
thereafter, using aQuantitativeMovementAssessment system that
utilized force transducers toassess elbowflexionand extension (kg)
and hand grip (kg). For assessments of elbow muscle function,
patients were placed supine with a strap attached to a cuff worn
around the wrist; the opposite end of the strap was attached to the
force transducer, which was secured to a stable frame. Hand grip
function was evaluated while patients were sitting with their feet
supported and the elbow positioned at a 90-degree angle. Patients
completed a minimum of 3 trials. If the third trial produced the
greatest value, up to 2 additional trials were then performed until
either a maximum effort was achieved or 5 trials were completed.
The maximum value for each muscle group was recorded.
2.4. Genetic diagnosis
Genetic mutation analysis was performed at Nationwide
Children’s Hospital as part of the study criteria. The presence
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of out-of-frame deletion(s) that could be corrected by skipping
exon 51 (e.g., deletion mutations of exons 45–50, 47–50, 48–50,
49–50, 50, 52, or 52–63) were confirmed in a Clinical Laboratory
Improvement Act–accredited laboratory by any peer-reviewed
and published methodology that evaluates all exons. This
methodology included, but was not limited to, multiplex
ligation-dependent probe, comparative genomic hybridization,
and single condition amplification/internal primer analysis.
2.5. Dystrophin assessments
2.5.1. Muscle biopsies. Details of muscle biopsy procedures
conducted in studies 201 and 202 were described previously.[2,11]
Eleven patients consented to an additional, optional fourth
biopsy of the contralateral deltoid at week 180. A total of
9 baseline comparator muscle biopsies were also evaluated,
including 3 baseline samples from studies 201 and 202 and
6 biceps biopsy samples from the eteplirsen PROMOVI clinical
trial (NCT02255552), a study with comparable inclusion criteria
to studies 201 and 202.
2.5.2. Western immunoblot for dystrophin. Muscle biopsy
tissue sections were homogenized in buffer containing 4M urea
(Teknova; Hollister, California), 125-mMTris pH 6.8 (Amresco;
Solon, OH), 4% sodium dodecyl sulfate solution (Fisher;
Loughborough, UK), and 1 complete mini protease inhibitor
tablet/7-mL buffer (Roche; Basel, Switzerland). A total protein
assay of the tissue extract was performed with the RCDC Protein
Assay Kit II per the manufacturer’s instructions (BioRad;
Hercules, CA). For each patient sample, 50mg total protein
was loaded onto a NuPAGE Novex 10 well, 1-mm, mini 3% to
8% polyacrylamide Tris-acetate gel (Life Technologies; Carls-
bad, CA), followed by transfer onto Invitrolon polyvinylidene
difluoride (PVDF) membranes (Life Technologies; Carlsbad,
CA). Dystrophin was detected by incubation PVDF membranes
with 1:20 dilution of DYS1 (Leica; Wetzlar, Germany) followed
by 1:40,000 anti-mouse IgG-conjugated horseradish peroxidase
(GE Healthcare; Little Chalfont, UK). Signal from the membrane
was developed using ECL Prime Buffer (GEHealthcare) followed
by film exposure. Western blot films were analyzed using
ImageQuant TL Plus software version 8.1 (GE Healthcare), and
linear regression analysis was performed using GraphPad
software. To determine the percent dystrophin in a sample,
dystrophin band intensities as well as the input percent of normal
control (NC) were log-transformed, and linear regression
analysis was performed on the log-transformed data. The percent
NC was then calculated using the equation: %NC=10^((LOG
(band intensity)-y intercept)/slope).
2.5.3. Percent dystrophin-positive fibers. The methodology
for immunohistochemical staining was described previously.[2,11]
Dystrophin-positive fibers were manually scored by independent,
blinded analysts at Nationwide Children’s Hospital and at
Flagship Biosciences from randomized digital images of muscle
biopsies stained using indirect immunofluorescence labeling with
the primary antibody MANDYS106.
2.5.4. Bioquant analysis. Bioquant Life Sciences imaging
software (Bioquant Image Analysis Corporation; Nashville,
TN) was used to quantify relative dystrophin levels associated
with muscle fiber membranes by measuring relative fluorescence
levels from blinded, randomized digital images of muscle biopsies
stained using indirect immunofluorescence labeling with
the primary antibody MANDYS106 (Developmental Studies
Hybridoma Bank; University of Iowa, Department of Biology,
Iowa City, IA). Percent intensity was calculated for each test
sample relative to the NC value, as previously described.[2,11]
2.6. Safety assessments
Safety assessments included the review and evaluation of
treatment-emergent adverse events (TEAEs), physical examina-
tions, vital signs, clinical laboratory testing, and the use of
concomitant medications.
2.7. Statistical analysis
Baseline was defined as the last value prior to the first dose of
eteplirsen. For the 6MWT, a distance of 0 m was used if the
patient was unable to complete the 6MWT. Fold difference in
PDPF and Bioquant intensity at week 180 was calculated as the
mean in the eteplirsen group divided by the mean in the untreated
control group. P values comparing eteplirsen patients versus
untreated controls for dystrophin assessments (Western blot,
PDPF, and fiber intensity) were calculated using a 2-sample t test,
with statistical significance set at P< .05. For safety data, TEAEs
were summarized using descriptive statistics.
3. Results
The patients who lost ambulation (patients A and B) were
identical twin brothers, started ambulating independently at
16 months of age, were initially randomized to the eteplirsen
30-mg/kg treatment group, and remained on eteplirsen
30mg/kg/week throughout the study. They were aged 9.9 years
at study enrollment compared with a mean age for the remaining
10 patients (patients C–L) of 9.2 years (range, 7.4–11.0). Patient
A had a body mass index (BMI) of 20.9kg/m2 and weighed
39.8kg; patient B had a BMI of 21.5kg/m2 and weighed 39.7kg.
In comparison, the mean BMI of the remaining 10 patients was
20.3kg/m2 (range, 16.4–25.6kg/m2), and their mean weight was
29.9kg (range, 22.1–38.3kg). Baseline demographics and disease
characteristics for all 12 male patients who completed the studies
have been described previously.[2,10] Overall, the DMD gene
mutations of all 12 patients represented 5 genotypes that caused
out-of-frame deletions eligible for exon 51 skipping (deletion
mutation of exons 45–50, 48–50, 49–50, 50, and 52)[2]; patients
A and B had a deletion mutation of exons 45–50 as did 2 of the
other 10 patients. Patients A and B lost ambulation at
approximately week 36 while the other 10 patients remained
ambulatory throughout the study.
As part of their preventive cardiovascular regimen, patients A
and B were receiving losartan 25mg once daily throughout the
study, and carvedilol 3.125mg twice daily until week 109, when
they were switched to 6.25mg twice daily and were maintained at
that dose through the remainder of the study. Seven of the 10
patients who remained ambulatory were also taking concomitant
medications as preventive cardiovascular regimens. Patients A and
Bwerealso takingalbuterol asneeded formild asthma.The current
daily medication regimen for patients A and B includes prednisone
40mg, carvedilol 6.25mg, eplerenone 0.5mg, and losartan 25mg.
3.1. Ambulation
The baseline 6MWT distances of patients A and B, 330 m and
256 m, respectively, were lower than the mean 6MWT distance
of 376.4 m (range, 341–418 m) observed in the remaining
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10 patients (Fig. 1). Longitudinally, patient A had a 6MWT
distance of 50 m at week 24, 12 m at week 32, and 0 m at week
36; patient B had 6MWT distances of 17, 3, and 0 m at weeks 24,
32, and 36, respectively. The mean 6MWT distances achieved by
the 10 ambulatory patients at weeks 24 and 36 were 381.8 m
(range, 325–431 m) and 359.5 m (range, 302–458 m),
respectively (Fig. 2).
3.2. Pulmonary function
Patients A and B experienced an initial decline in percent
predicted forced vital capacity (FVC%p), followed by a period of
stability through week 96. Their FVC%p values subsequently
declined between weeks 96 and 120, and again plateaued for the
duration of the study (Fig. 3A). Values for FVC%p at week 240 in
the nonambulatory twins were 80% for patient A and 72% for
patient B. The study mean at week 240 for the ambulatory
patients treated with eteplirsen was 92% (range, 61–112%). At
the time of this writing, patients A and B were aged 16 years and
had initiated intermittent, nocturnal ventilation at age 15.
3.3. Cardiac function
Both twins maintained normal LVEF throughout the study
(Fig. 3B), with values similar to study means through week 240.
The LVEF values for patients A and B at week 240were 66% and
58%, respectively. Similarly, the study mean at week 240 for
the eteplirsen-treated ambulatory patients was 61% (range,
50–70%).
3.4. Upper limb function
Measures of upper limb function in the twins were reasonably
stable (Fig. 4). For patient A, mean values at week 240were 0:22 s
for the 9-Hole Peg Test, 9.18kg for dominant (right) hand grip
strength, 0.81kg for right elbow flexion, and 2.39kg for right
elbow extension at week 240. For patient B, mean values at week
240 were 0:31 s for the 9-Hole Peg Test, 9.60kg for dominant
hand grip strength, 1.44kg for right elbow flexion, and 2.24kg
for right elbow extension. The 0:31 s 9-Hole Peg Test time for
patient B may have resulted from a spinal fusion surgery















































Ambulatory eteplirsen mean (n=10)
Figure 2. Rapid decline and loss of ambulation in the eteplirsen-treated twin patients. 6MWT=6-minute walk test.
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patient B achieved a 9-Hole Peg Test completion time of 21 s.
Taking this time point into consideration, overall, these findings
were similar to study means for the 10 ambulatory patients
through week 240, which were 0:19 s (9-Hole Peg Test), 7.5kg
(dominant hand grip strength), 1.77kg (right elbow flexion), and
2.97kg (right elbow extension). Currently, neither patient A nor
B has developed hand contractures. In addition, both patients are
generally able to feed themselves and to utilize computers or
handheld devices to complete their schoolwork. They both
require some assistance with hand transfer, particularly with
heavy objects.
3.5. Dystrophin levels
Dystrophin expression was assessed in 11 patients (patients A
and B and 9 other patients) who provided consent for the week
180 biopsy, which was analyzed by 3 methods, including
Western blot (% normal controls), percent dystrophin-positive
fibers (PDPF), and fiber intensity (% intensity based on
fluorescence; Fig. 5; Table 1). Patients A and B had higher
dystrophin expression as measured by all 3 methods (patient A:
0.52%, 40.4%, and 23.0%, respectively; patient B: 1.62%,
44.4%, and 21.4%, respectively) relative to the untreated
comparator group (0.08%, 5.04%, and 9.4%, respectively)
and had comparable or greater dystrophin expression relative to
the mean of the ambulatory eteplirsen-treated patients (0.90%,
36.2%, and 22.7%, respectively). The difference in dystrophin
expression between the mean of the untreated controls and the
mean of the 11 eteplirsen-treated patients was also evaluated and
found to be statistically significant for all 3 measures (Western
blot, P< .01; PDPF, P< .001; fiber intensity, P< .001; Table 1).
As reported by Charleston et al,[11] these differences equated to
an 11.6-fold difference by Western blot, a 7.4-fold difference by
PDPF, and a 2.4-fold difference by Bioquant fluorescence
intensity. The PDPF results were confirmed by 3 pathologists
who independently scored the image sets and observed a 15.5-
fold difference between the untreated controls and the treated
patient population.
3.6. Safety
All 12 patients experienced at least 1 TEAE. The most commonly
reported TEAE, procedural pain, was reported by 11 of
















Ambulatory eteplirsen mean (n=10)
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Figure 3. Measures of pulmonary and cardiac function in patients A and B versus studymean through 240 weeks of eteplirsen treatment: (A) FVC%p and (B) LVEF.
FVC%p=percent predicted forced vital capacity, LVEF= left ventricular ejection fraction.
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to 240 weeks of eteplirsen treatment in the combined studies 201
and 202 are shown in Table 2; TEAEs that occurred during 24
weeks of treatment with placebo in study 201 were previously
reported.[10]
The 2 patients who lost ambulation experienced TEAEs that
were similar in frequency and severity to those of the 10 patients
who remained ambulatory throughout the study. A total of 34
and 38 TEAEs were reported for patients A and B, respectively,
compared with a range of 36 to 81 TEAEs reported for the 10
patients who remained ambulatory. Six of 12 patients (50.0%)
experienced TEAEs that were considered by the investigator to be
related to eteplirsen. Patients A and B both experienced fibrin
clots in a chest port placed for eteplirsen infusion intravenous
access (week 136 in patient A, weeks 137 and 164 in patient B),
which were considered to be non-serious TEAEs of moderate
severity, possibly or probably related to the study drug.
Four of 12 patients (33.3%) experienced serious adverse
events. Both patient A and patient B experienced serious adverse
events that were considered by the investigator to be unrelated to
eteplirsen treatment. At week 87, approximately 51 weeks after
loss of ambulation, patient A sustained a severe, closed, stable
fracture of the right distal femur after falling out of his
wheelchair; he recovered 2 months later. During week 171,
approximately 31 months after loss of ambulation, patient B
experienced a non-serious event of moderate scoliosis related to
DMD progression that was not considered treatment-related.
During week 212, approximately 40 months after loss of
ambulation, worsening of the scoliosis was noted and the patient
underwent posterior spinal fusion surgery, which was considered
serious. At the time of this writing, both patients A and B had
undergone scoliosis surgery. Patient B experienced complications
from this surgery, including postoperative anemia, cardiac
function disturbance, and postoperative respiratory distress.
4. Discussion
Two patients with DMD who were enrolled in a clinical trial of
eteplirsen lost ambulation but maintained relative stability on
nonambulatory measures of disease progression. Through 240
weeks of eteplirsen treatment in combined studies 201 and 202,
both patients demonstrated cardiac and upper limb function as
well as dystrophin production similar to that of 10 ambulatory
patients evaluated. Compared with the other study patients at
initiation of eteplirsen treatment, the twin patients were further
progressed in key measures of disease considered to be predictive
of loss of ambulation. These measures included advanced age
(>7 years) and shorter 6MWT distance (330m).[2] Natural
history studies show that age and 6MWT distance are predictive
of disease progression.[15,16] A 3-year, prospective, longitudinal
natural history study in ambulatory boys with DMD showed that
the greatest decline in patients older than 7 years occurred in
those who had 6MWT distances <350 m at baseline.[15]
Previous studies reported dystrophin expression at baseline
and following 12 or 24 weeks of treatment with eteplirsen, with
an increase in the PDPF at week 24 but not at week 12. These
findings suggest that a period of treatment with eteplirsen is
needed before an increase in dystrophin may be detected.[2]
Therefore, given that the twins showed more advanced disease at
trial initiation, it is not surprising that they lost ambulation early
in the study. However, their stability on non-ambulatory
outcome measures suggests a potential therapeutic benefit of
eteplirsen. This is supported by the observation that both
Patient A
Patient B































































































Figure 4. Measures of upper limb function in patients A and B versus studymean through 240 weeks of eteplirsen treatment: (A) 9-Hole Peg Test; (B) grip strength;
(C) elbow flexion; and (D) elbow extension. All data represent the right hand, which was the dominant hand for all 12 patients.
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nonambulatory twin patients demonstrated a similar level of
increased novel dystrophin compared with ambulatory patients
following 180 weeks of treatment.[2] Dystrophin production was
demonstrated by 3 independent measures—Western blot, PDPF,
and fiber intensity—that effectively assess dystrophin quantity
and correct localization of dystrophin to the sarcolemma
membrane.[11]
Pulmonary function assessments showed that FVC%p de-
clined initially and again between weeks 96 and 120, then
remained stable for the duration of the study. Values for FVC%p
at week 240 were 80% and 72% for patients A and B,
respectively, and 92% for the ambulatory study mean. Pulmo-
nary dysfunction is a key contributor to morbidity and mortality
in patients with DMD.[17–19] FVC%p is an accurate spirometry
measure that has been recommended as a reproducible, sensitive
method for monitoring pulmonary function in DMD clinical
trials.[20,21] Multiple publications investigating pulmonary
function in DMD disease natural history report continual
declines in FVC%p.[22–24] Interestingly, in a prospective
follow-up of nonambulatory men and boys with DMD employ-
ing a natural history trial design, FVC%p remained stable
over 12 months (61.0–61.8%), but declined significantly over
24 months from 60% to 54.4% (P= .02).[24]
With regard to cardiac function, LVEF values for the
nonambulatory twin patients remained stable and within the
normal range throughout 240 weeks of treatment with eteplirsen
and were similar to the mean LVEF value of the 10 ambulatory
patients. Decline in cardiac function, including LVEF decline by
orthogonal measures, is reported in the natural history

























































































































Figure 5. Dystrophin expression following 180 weeks of eteplirsen treatment, based on Western blot analysis and immunohistochemistry (A), Western blot
image (B), PDPF (C), and the intensity of dystrophin fluorescent signal in muscle fibers (D). In panels A, C, and D, standard deviations are represented by error bars.
In panel B, lanes in the Western blot image are identified left to right as the standard curve (4%, 2%, 1%, 0.5%, 0.25% of normal), patient samples (treated or
untreated in blinded random order in next two lanes), and negative pooled DMD control sample. Patient samples representing patient A and patient B are identified
in both figures. Note that either an unrelated patient sample representing an untreated (left figure) or treated (right figure) patient was run on the adjacent lane due to
the random blinded nature that samples were evaluated. DMD=Duchenne muscular dystrophy, PDPF=percent dystrophin-positive fibers, tx= treated, untx=
untreated.
Table 1
Novel dystrophin production confirmed by Western blot, fiber






Patient A 0.52 23.0 40.4
Patient B 1.62 21.4 44.4
Ambulatory eteplirsen mean (n=9) 0.90 22.7 36.2
Untreated mean (n=9) 0.08 9.4 5.04
All eteplirsen mean (n=11) 0.93 22.6 37.3
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in patients with DMD.[28] It should be noted that ECHO
evaluation of LVEF is not as sensitive as orthogonal LVEF
measurements by imaging modalities such as cardiac magnetic
resonance imaging or radionuclide ventriculography. At a
minimum, it can be stated that eteplirsen did not have an
obvious negative impact on cardiac function during the duration
of the trial.
Regarding the 9-Hole Peg Test, a separate study of healthy
reference individuals reported mean completion times for the
9-Hole Peg Test of 19.9 s for boys aged 8 to 9 years that decreased
steadily to 18.0 s for boys aged 14 to 15 years.[14] As expected,
mean completion times are higher for patients with DMD; a
prospective, natural history study of nonambulatory patients
with DMD reported a mean 9-Hole Peg Test completion time at
baseline of 27.2 s, which did not change significantly over 1 or 2
years of follow-up.[24] In the current report, mean 9-Hole-Peg
Test completion times were similar for the nonambulatory twin
patients compared with the ambulatory eteplirsen mean through
week 216, followed by a slowing of completion time for patient B
at week 240. This observation in patient B may have been
attributable to a spinal fusion surgery conducted prior to week
240, as this surgical procedure often results in loss of function
resulting from change in movement patterns. Notably, at week
216, patient B achieved a 9-Hole Peg Test completion time of 21 s.
Studies of upper limb function in nonambulatory patients have
shown a decline in measures of grip strength and elbow flexion,
over a period of 12 to 24 months.[24,29] In the present study,
dominant-hand grip strength of nonambulatory patients A and B
remained remarkably stable throughout the study, particularly
following confirmation of dystrophin expression at week 24, and
was similar to or greater than the mean grip strength of
ambulatory patients. Right elbow flexion declined over time, and
right elbow extension remained relatively stable and was similar
to that of the mean of the other patients throughout the study.
Neither patient A nor B developed hand contractures, a
complication of DMD resulting from the absence of dystrophin
that can substantially limit functioning and potentially limit the
ability to administer and interpret commonly used tests of upper
arm function and strength.[20,30] Importantly, both patients A
and B retained anti-gravity arm function, which is vital to
activities of daily living.
Weekly administration of eteplirsen was well tolerated through
240 weeks of treatment in the nonambulatory patients. The
TEAEs experienced by these patients were similar in nature and
frequency to those reported for ambulatory patients. Twin
patients A and B each experienced 1 serious TEAE of fracture and
scoliosis, respectively, which were considered unrelated to
treatment with eteplirsen. Moreover, these TEAEs are not
unexpected in patients diagnosed with DMD, as their fracture
risk is substantially higher compared with age- and sex-matched
individuals without DMD,[31] and the development of scoliosis is
not uncommon in nonambulatory patients with DMD.[5,32]
Limitations to these studies include the observational nature of
this analysis, the small number of patients evaluated, and the
open-label nature of treatment in the extension study.
In conclusion, after loss of ambulation, disease progression
was relatively stable in twin patients treated with eteplirsen and
was similar to the mean of the study patients who remained
ambulatory. The 2 patients who lost ambulation had the most
progressed disease at initiation of treatment, experienced a rapid
decline in ambulatory ability prior to confirmation of dystrophin
production, and lost ambulation shortly thereafter. However,
both patients experienced relative stability on nonambulatory
outcome measures. Each twin patient experienced maintenance
of normal cardiac function and stability of upper limb function
after losing ambulation. Sustained dystrophin expression was
confirmed in both patients following 180 weeks of eteplirsen
treatment by 3 complementary dystrophin assays. This observa-
tional study highlights the potential benefit of eteplirsen in
patients who are non-ambulatory or who lose ambulation during
the course of treatment. As additional eteplirsen clinical trials
progress, further evidence will become available to provide
context for these clinical observations.
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At least 1 TEAE 12 (100)
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Oropharyngeal pain 8 (66.7)
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Pyrexia 3 (25.0)
TEAE= treatment-emergent adverse event.
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